Concern about abuse/dependence in chronic pain patients taking opioid analgesics may lead
to undertreatment of pain, yet little is known about the prevalence of abuse/dependence in …

Tramadol HCl, marketed as Ultram® in the USA, was introduced as a non-scheduled drug
in April 1995 based on the assumption that the risk of abuse was sufficiently low to warrant a …

As the nontherapeutic use of prescription medications escalates, serious associated
consequences have also increased. This makes it essential to estimate misuse, abuse, and related …

Opioid analgesics remain the cornerstone of effective management for moderate-to-severe
pain. In the face of persistent lack of access to opioids by patients with legitimate pain …

In 1994, the Drug Abuse Advisory Committee (DAAC) of the Food and Drug Administration (FDA)
concluded that Ultram ® (tramadol hydrochloride) could be marketed as an analgesic …

Background/Purpose Little information exists on the comparative patient and economic burden
of chronic widespread pain ( CWP ) and fibromyalgia ( FM ) in the United States. Methods …

Increased abuse and diversion of prescription opioids has been a consequence of the
increased availability of opioids to address the widespread problem of undertreated pain. Opioid …

Purpose The analgesic Tramadol HCl (Ultram™) was approved in 1994 as a non‐scheduled
drug under the CSA provided that a novel risk‐management program would be developed …

This article discusses the use of patient satisfaction and personal health care experiences
as a measure of health care quality. It also presents a field-proven patient experience and …

Issues regarding the use of epidemiology in drug abuse research are discussed and systems
for monitoring national trends and identifying risk factors are described. Data indicate a …